Modulation of single slow (L-type) calcium channels by intracellular ATP in vascular smooth muscle cells.
Involvement of ATP in the regulation of slow (L-type) Ca2+ channels of vascular smooth muscle cells was investigated by recording single Ca2+ channel currents (single-channel conductance of 18 pS) using a patch clamp technique. In the cell-attached configuration, intracellular composition was modified by permeabilizing the cell membrane with mechanical disruption at one end of the cell. Single cells were freshly isolated from guinea-pig portal vein by collagenase treatment. For the channel recordings, the pipette solution contained 100 mM Ba2+ and the bath contained K+-rich solution (with 5 mM EGTA) to depolarize the membrane to near 0 mV. The channel activity decreased usually within 3 min after permeabilizing the cell end and exposure to ATP-free bath solution. If ATP (1-5 mM) was applied to the bath (access to cell interior) before complete disappearance of channel activity, channel activity was partially recovered. ATP did not change the current amplitude (i) or the mean open time of the channels, whereas the number of channels available for opening and/or the probability of their being open (NPo) were increased by ATP. A non-hydrolyzable analogue of ATP, AMP-PNP, did not exert an ATP-like effect; ATP-gamma-S had a weak effect. With 1 microM Bay-K-8644 (Ca2+ channel agonist) in the pipette, the activity of the Ca2+ channel was high; such activity persisted for more than 10 min after permeabilizing the cell and exposing to ATP-free solution containing KCN (1 mM) and 2-deoxy-D-glucose (10 mM).(ABSTRACT TRUNCATED AT 250 WORDS)
Ohya
Y
Y
Department of Physiology and Biophysics, University of Cincinnati, College of Medicine, OH 45267.
Sperelakis
N
N
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001464:Barium / Q000494:pharmacology; D002118:Calcium / Q000493:pharmacokinetics*; D015220:Calcium Channels / Q000187:drug effects* / Q000502:physiology; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D002463:Cell Membrane Permeability / Q000187:drug effects; D006168:Guinea Pigs; D008564:Membrane Potentials / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D010766:Phosphorylation; D011188:Potassium / Q000494:pharmacology
D015220:Calcium Channels; D001464:Barium; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D000255:Adenosine Triphosphate; D011188:Potassium; D002118:Calcium